T2018-001:A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy.
TACL, T2018-001
What is the goal of the study?
Primary Objectives: -To estimate the complete response rate and minimal residual disease (MRD) response rate in patients with refractory or relapsed (first and subsequent) B-ALL, B-LLy, T-ALL, and T-LLy treated with curative intent, and to identify disease, patient and treatment characteristics that influence this rate. - To estimate the incidence of treatment related mortality (TRM) occurring in these patients during salvage treatment and to identify disease, patient and treatment characteristics that influence this rate. Secondary Objective -To estimate the event free survival (EFS) and overall survival (OS) probability in patients with refractory or relapsed (first and subsequent) B-ALL, B-LLy, T-ALL, and T-LLy treated with curative intent, and to identify disease, patient and treatment characteristics that influence these probabilities. - To estimate the proportion of patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) after initiation of salvage therapy and their subsequent EFS and OS probabilities. 1.2.3 To estimate the proportion of patients who receive chimeric antigen receptor (CAR) T-cell therapy and their subsequent EFS and OS probabilities
Who can participate in the study?
Please contact the study team listed below to learn more.